Eloxx Pharmaceuticals (NASDAQ:ELOX – Get Free Report) is one of 903 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Eloxx Pharmaceuticals to related businesses based on the strength of its institutional ownership, analyst recommendations, risk, dividends, valuation, profitability and earnings.
Institutional & Insider Ownership
2.9% of Eloxx Pharmaceuticals shares are held by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are held by institutional investors. 25.9% of Eloxx Pharmaceuticals shares are held by insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.
Profitability
This table compares Eloxx Pharmaceuticals and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Eloxx Pharmaceuticals | N/A | N/A | N/A |
| Eloxx Pharmaceuticals Competitors | -2,299.87% | -222.98% | -17.45% |
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Eloxx Pharmaceuticals | 1 | 0 | 2 | 1 | 2.75 |
| Eloxx Pharmaceuticals Competitors | 7577 | 13645 | 25432 | 996 | 2.42 |
Eloxx Pharmaceuticals currently has a consensus price target of $41.50, indicating a potential upside of 176.67%. As a group, “Pharmaceuticals” companies have a potential upside of 30.04%. Given Eloxx Pharmaceuticals’ stronger consensus rating and higher possible upside, equities research analysts plainly believe Eloxx Pharmaceuticals is more favorable than its rivals.
Earnings & Valuation
This table compares Eloxx Pharmaceuticals and its rivals revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Eloxx Pharmaceuticals | $6.36 million | -$5.99 million | -9.74 |
| Eloxx Pharmaceuticals Competitors | $3.47 billion | $3.12 billion | 545.94 |
Eloxx Pharmaceuticals’ rivals have higher revenue and earnings than Eloxx Pharmaceuticals. Eloxx Pharmaceuticals is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Volatility & Risk
Eloxx Pharmaceuticals has a beta of -1862.26, suggesting that its stock price is 186,326% less volatile than the S&P 500. Comparatively, Eloxx Pharmaceuticals’ rivals have a beta of -3.13, suggesting that their average stock price is 413% less volatile than the S&P 500.
Summary
Eloxx Pharmaceuticals beats its rivals on 7 of the 13 factors compared.
About Eloxx Pharmaceuticals
Eloxx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. It engaged in developing novel small molecule medicines to treat many rare and ultra-rare genetic diseases caused by nonsense mutations. The company’s lead product candidate consists ELX-02, is an optimized aminoglycoside designed to restore full-length functional proteins. It operates primarily in Waltham, MA and Rehovot, Israel. Eloxx Pharmaceuticals Inc., formerly known as Sevion Therapeutics Inc., is based in WALTHAM, United States.
Receive News & Ratings for Eloxx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eloxx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
